Education
About Us
Working with TipRanks
Follow Us
Gaush Meditech Ltd. (HK:2407)
:2407
2407 Stock Chart & Stats
HK$7.64
-HK$0.07(-0.81%)
At close: 4:00 PM EST
HK$7.64
-HK$0.07(-0.81%)
Day’s Range― - ―
52-Week RangeHK$4.80 - HK$9.99
Previous CloseN/A
Volume488.20K
Average Volume (3M)147.22K
Market Cap
HK$1.05B
Enterprise ValueHK$999.37M
Total Cash (Recent Filing)HK$383.68M
Total Debt (Recent Filing)HK$469.06M
Price to Earnings (P/E)9.5
Beta0.77
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.48%
Share Statistics
EPS (TTM)0.29
Shares Outstanding147,887,860
10 Day Avg. Volume84,250
30 Day Avg. Volume147,220
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)0.87
Price to Sales (P/S)0.96
P/FCF Ratio51.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageAn improved debt-to-equity ratio (0.35) reduces financial leverage and interest burden, increasing balance sheet flexibility. That strengthens capacity to fund R&D, scale production or absorb shocks, lowering refinancing risk and supporting strategic moves over the next 2–6 months.
Stable Revenue GrowthConsistent revenue growth (~2.9% in 2024) signals steady end-market demand and helps sustain scale benefits. For a medical-device company, moderate yet stable top-line expansion supports capacity utilization, long-term customer relationships and more predictable operating planning over the medium term.
Ongoing ProfitabilityMaintaining profitability despite margin pressure demonstrates underlying business viability and pricing/clinical competitiveness. Continued earnings provide internal resources for product development and operations, preserve creditor confidence and give the company a cushion to navigate sector-specific investments.
Bears Say
Declining MarginsFalling gross and net margins indicate pressure from higher input or operating costs or pricing stress. Sustained margin deterioration will erode earnings power and ROE, limit reinvestment capacity and require operational improvements or pricing adjustments to restore long-term profitability.
Free Cash Flow DeclineA 25.59% drop in free cash flow materially weakens internally generated funding for capex, R&D and dividends. If persistent, lower FCF could force higher borrowing or capital rationing, reducing strategic flexibility and increasing reliance on external financing in a capital-intensive med-tech environment.
Weak Cash ConversionLow operating cash flow relative to net income signals poor cash conversion, possibly from receivables, inventory or other working-capital strains. This raises liquidity risk, can constrain near-term operational spending, and may necessitate balance-sheet actions if not improved.
Gaush Meditech Ltd. News
2407 FAQ
What was Gaush Meditech Ltd.’s price range in the past 12 months?
Gaush Meditech Ltd. lowest stock price was HK$4.80 and its highest was HK$9.99 in the past 12 months.
What is Gaush Meditech Ltd.’s market cap?
Gaush Meditech Ltd.’s market cap is HK$1.05B.
When is Gaush Meditech Ltd.’s upcoming earnings report date?
Gaush Meditech Ltd.’s upcoming earnings report date is Apr 01, 2026 which is in 36 days.
How were Gaush Meditech Ltd.’s earnings last quarter?
Gaush Meditech Ltd. released its earnings results on Aug 28, 2025. The company reported HK$0.294 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.294.
Is Gaush Meditech Ltd. overvalued?
According to Wall Street analysts Gaush Meditech Ltd.’s price is currently Overvalued.
Does Gaush Meditech Ltd. pay dividends?
Gaush Meditech Ltd. pays a Annually dividend of HK$0.3 which represents an annual dividend yield of 3.48%. See more information on Gaush Meditech Ltd. dividends here
What is Gaush Meditech Ltd.’s EPS estimate?
Gaush Meditech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gaush Meditech Ltd. have?
Gaush Meditech Ltd. has 147,887,860 shares outstanding.
What happened to Gaush Meditech Ltd.’s price movement after its last earnings report?
Gaush Meditech Ltd. reported an EPS of HK$0.294 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.139%.
Which hedge fund is a major shareholder of Gaush Meditech Ltd.?
Currently, no hedge funds are holding shares in HK:2407
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gaush Meditech Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.77%
12-Months-Change
Fundamentals
Return on Equity
6.33%
Trailing 12-Months
Asset Growth
-6.56%
Trailing 12-Months
Company Description
Gaush Meditech Ltd.
Gaush Meditech Ltd., together with its subsidiaries, researches and develops, produces, and sells ophthalmic medical devices in the People's Republic of China and internationally. The company operates through Proprietary Products, Distribution, Technical, and Others segments. Its ophthalmic medical devices are used for diagnosis, treatment, or surgeries, including vitreoretinal diseases, cataract, glaucoma, refractive surgery, ocular surface diseases, optometry, and pediatric ophthalmology. The Proprietary Products segment develops and produces surgical equipment and related supporting software, intra optical lens, and ophthalmic disease diagnosis and treatment equipment and related supporting consumables. The Distribution segment sells diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment, and related supporting consumables. The Technical segment provides warranty services, maintenance services, and after-sales services related consumables. The Others segment engages in the provision of equipment leasing and agent registration services; and licensing intellectual properties. The company sells its products directly and through distributors to public and private hospitals, and other customers. Gaush Meditech Ltd. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
Technical Analysis
China Isotope & Radiation Corp.
―
EuroEyes International Eye Clinic Limited
―
JW (Cayman) Therapeutics Co. Ltd.
―
Broncus Holding Corp.
―
Zhaoke Ophthalmology Ltd.
―
Options Prices
Currently, No data available
---